162401-32-3 | Roflumilast

Packsize	Purity	Availability	Price	Discounted Price
5mg	99+%	in stock	$6.00	$4.00
10mg	99+%	in stock	$8.00	$6.00
50mg	99+%	in stock	$11.00	$8.00
250mg	99+%	in stock	$16.00	$11.00
1g	99+%	in stock	$35.00	$25.00
5g	99+%	in stock	$126.00	$88.00
25g	98%	in stock	$589.00	$412.00
100g	98%	in stock	$2,004.00	$1,403.00

Description

• Catalog Number: AA84125
• Chemical Name: Roflumilast
• CAS Number: 162401-32-3
• Molecular Formula: C17H14Cl2F2N2O3
• Molecular Weight: 403.2075
• MDL Number: MFCD00938270
• SMILES: FC(Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl)F

Computed Properties

• Complexity: 475
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 7
• XLogP3: 4.6

Literature

• The molecular basis for the inhibition of phosphodiesterase-4D by three natural resveratrol analogs. Isolation, molecular docking, molecular dynamics simulations, binding free energy, and bioassay.

  Biochimica et biophysica acta 20131001

• Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC-MS/MS: application for a pharmacokinetic study.

  Journal of mass spectrometry : JMS 20121201

• [Chronic obstructive pulmonary disease : new pharmacotherapeutic options].

  Der Internist 20121101

• The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice.

  Diabetologia 20121001

• Alternatives to indicating roflumilast and the chronic obstructive pulmonary disease classification.

  Archivos de bronconeumologia 20120901

• Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.

  The Journal of clinical endocrinology and metabolism 20120901

• Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.

  Archivos de bronconeumologia 20120701

• Superiority of PC-SOD to other anti-COPD drugs for elastase-induced emphysema and alteration in lung mechanics and respiratory function in mice.

  American journal of physiology. Lung cellular and molecular physiology 20120615

• Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation.

  The Journal of physiology 20120601

• Physiological effects of roflumilast at rest and during exercise in COPD.

  The European respiratory journal 20120501

• Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure.

  Kidney international 20120501

• Can we cure HIV-1-associated nephropathy in transgenic mice?

  Kidney international 20120501

• Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120415

• Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.

  Pulmonary pharmacology & therapeutics 20120401

• Roflumilast: a novel treatment for chronic obstructive pulmonary disease.

  The Annals of pharmacotherapy 20120401

• Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.

  British journal of pharmacology 20120301

• Lack of involvement of type 7 phosphodiesterase in an experimental model of asthma.

  The European respiratory journal 20120301

• New drugs 2012 part I.

  Nursing 20120301

• Clinical Considerations for Roflumilast: A New Treatment for COPD.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20120301

• Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.

  Bioorganic & medicinal chemistry letters 20120215

• Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor.

  International immunopharmacology 20120101

• Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.

  International immunopharmacology 20120101

• Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

  Clinical therapeutics 20120101

• Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.

  Respiratory research 20120101

• Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.

  International journal of chronic obstructive pulmonary disease 20120101

• Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.

  International journal of chronic obstructive pulmonary disease 20120101

• Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.

  Swiss medical weekly 20120101

• LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing.

  PloS one 20120101

• [Current anti-inflammatory therapy in patients with chronic obstructive pulmonary disease].

  Terapevticheskii arkhiv 20120101

• Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.

  Journal of medicinal chemistry 20111208

• Pharmacokinetic evaluation of roflumilast.

  Expert opinion on drug metabolism & toxicology 20111201

• [New goals in COPD treatment. From symptom control to prevention of exacerbations].

  MMW Fortschritte der Medizin 20111201

• Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.

  Respirology (Carlton, Vic.) 20111101

• [Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].

  Deutsche medizinische Wochenschrift (1946) 20111101

• Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.

  European journal of medicinal chemistry 20111001

• Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.

  The European respiratory journal 20110901

• PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease.

  Pulmonary pharmacology & therapeutics 20110801

• The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion.

  Journal of cellular physiology 20110801

• Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.

  International journal of clinical pharmacology and therapeutics 20110801

• Roflumilast (Daliresp) for COPD.

  The Medical letter on drugs and therapeutics 20110725

• Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects.

  Expert opinion on drug safety 20110701

• Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults.

  International journal of clinical pharmacology and therapeutics 20110701

• ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.

  International immunopharmacology 20110601

• Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects.

  International journal of clinical pharmacology and therapeutics 20110601

• Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

  The Cochrane database of systematic reviews 20110511

• Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

  British journal of pharmacology 20110501

• Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.

  Journal of clinical pharmacology 20110401

• No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.

  Journal of clinical pharmacology 20110401

• Roflumilast for severe COPD?

  Drug and therapeutics bulletin 20110401

• [COPD and diabetes mellitus. Does pulmonary medication modify blood glucose metabolism?].

  MMW Fortschritte der Medizin 20110317

• [Introduction].

  Revista clinica espanola 20110301

• [Phosphodiesterase-4 inhibitors: roflumilast].

  Revista clinica espanola 20110301

• [Pulmonary medicine. Two new drugs for the treatment of COPD].

  Revue medicale suisse 20110119

• Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats.

  British journal of pharmacology 20110101

• High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast.

  International journal of clinical pharmacology and therapeutics 20110101

• Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

  Respiratory research 20110101

• New therapeutic options in the management of COPD - focus on roflumilast.

  International journal of chronic obstructive pulmonary disease 20110101

• [New drugs in chronic obstructive pulmonary disease].

  Pneumonologia i alergologia polska 20110101

• No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.

  BMC clinical pharmacology 20110101

• Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.

  Clinical nurse specialist CNS 20110101

• Roflumilast, indacaterol maleate, and abiraterone acetate.

  Journal of the American Pharmacists Association : JAPhA 20110101

• Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.

  Journal of medical economics 20110101

• Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects.

  Respiratory research 20110101

• [A new alternative treatment in COPD: phosphodiesterase-4 inhibitors].

  Tuberkuloz ve toraks 20110101

• The use of roflumilast in COPD: a primary care perspective.

  Primary care respiratory journal : journal of the General Practice Airways Group 20101201

• Topical effects of roflumilast on 1-chloro-2,4-dinitrobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice.

  Die Pharmazie 20101201

• [Pharmacological profile of roflumilast].

  Archivos de bronconeumologia 20101201

• [Clinical profile of roflumilast].

  Archivos de bronconeumologia 20101201

• [Introduction. COPD treatment].

  Archivos de bronconeumologia 20101201

• Roflumilast for COPD.

  Drugs of today (Barcelona, Spain : 1998) 20101101

• Roflumilast for the treatment of chronic obstructive pulmonary disease.

  Expert review of respiratory medicine 20101001

• Roflumilast.

  Nature reviews. Drug discovery 20101001

• Roflumilast: clinical benefit in patients suffering from COPD.

  The clinical respiratory journal 20101001

• Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults.

  Chronobiology international 20101001

• Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

  Clinical pharmacokinetics 20100901

• Roflumilast: in chronic obstructive pulmonary disease.

  Drugs 20100820

• The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

  Pulmonary pharmacology & therapeutics 20100801

• Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung.

  British journal of pharmacology 20100801

• The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease.

  Therapeutic advances in respiratory disease 20100801

• [Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].

  Medizinische Monatsschrift fur Pharmazeuten 20100701

• Effect of cyclic AMP-elevating agents on airway ciliary beat frequency in central and lateral airways in rat precision-cut lung slices.

  European journal of pharmacology 20100610

• [Diseases of the lung and air passages 2010].

  Deutsche medizinische Wochenschrift (1946) 20100601

• Water-soluble PDE4 inhibitors for the treatment of dry eye.

  Bioorganic & medicinal chemistry letters 20100501

• New evidence in pulmonary and preventive medicine.

  Internal and emergency medicine 20100401

• Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.

  COPD 20100401

• Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.

  Expert opinion on pharmacotherapy 20100201

• The role of the phosphodiesterase-4 inhibitor, roflumilast, in chronic obstructive pulmonary disease.

  Polskie Archiwum Medycyny Wewnetrznej 20100101

• Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

  Drug design, development and therapy 20100101

• PDE4 inhibitors: a review of current developments (2005 - 2009).

  Expert opinion on therapeutic patents 20091101

• Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.

  British journal of clinical pharmacology 20091001

• The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.

  The Journal of pharmacology and experimental therapeutics 20090901

• Phosphodiesterase-4 inhibition in COPD.

  Lancet (London, England) 20090829

• Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

  Lancet (London, England) 20090829

• Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.

  Lancet (London, England) 20090829

• Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.

  The Journal of pharmacology and experimental therapeutics 20090701

• PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.

  American journal of physiology. Lung cellular and molecular physiology 20090601

• Roflumilast increases Clara cell secretory protein in cigarette smoke-exposed mice.

  COPD 20090601

• The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.

  Journal of clinical pharmacology 20090401

• Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.

  International journal of clinical pharmacology and therapeutics 20090401

• Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

  Journal of medicinal chemistry 20090326

• Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.

  Bioorganic & medicinal chemistry letters 20090301

• Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.

  British journal of pharmacology 20090201

• Effects of the phosphodiesterase type 4 inhibitor roflumilast on early and late allergic response and airway hyperresponsiveness in Aspergillus-fumigatus-sensitized mice.

  Pharmacology 20090101

• Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.

  Journal of clinical pharmacology 20081101

• Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.

  Journal of dermatological science 20080901

• Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial.

  Pulmonary pharmacology & therapeutics 20080801

• Anti-inflammatory modulation of chronic airway inflammation in the murine house dust mite model.

  Pulmonary pharmacology & therapeutics 20080801

• Development and characterisation of a novel and rapid lung eosinophil influx model in the rat.

  Pulmonary pharmacology & therapeutics 20080801

• Single-dose pharmacokinetics of roflumilast in children and adolescents.

  Journal of clinical pharmacology 20080801

• Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.

  Bioorganic & medicinal chemistry letters 20080715

• The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke.

  British journal of pharmacology 20080701

• PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.

  Cellular signalling 20080501

• Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20080501

• Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma.

  Expert opinion on investigational drugs 20080501

• Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.

  Pharmacology 20080101

• Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice.

  BMC pulmonary medicine 20080101

• [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].

  Tuberkuloz ve toraks 20080101

• Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.

  Thorax 20071201

• Treating COPD with PDE 4 inhibitors.

  International journal of chronic obstructive pulmonary disease 20071201

• Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.

  European journal of pharmacology 20071001

• Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.

  British journal of pharmacology 20071001

• Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070815

• The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.

  Journal of clinical pharmacology 20070801

• Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.

  American journal of respiratory and critical care medicine 20070715

• L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.

  Biochemical pharmacology 20070615

• PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.

  International journal of chronic obstructive pulmonary disease 20070601

• Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast.

  Journal of clinical pharmacology 20070501

• A reporter gene assay for screening of PDE4 subtype selective inhibitors.

  Biochemical and biophysical research communications 20070427

• Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.

  British journal of clinical pharmacology 20070301

• Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.

  Respiration; international review of thoracic diseases 20070101

• Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.

  Journal of clinical pharmacology 20070101

• Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.

  Clinical pharmacokinetics 20070101

• Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.

  Clinical pharmacokinetics 20070101

• A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

  PharmacoEconomics 20070101

• Evaluation of PDE4 inhibition for COPD.

  International journal of chronic obstructive pulmonary disease 20061201

• Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.

  International journal of clinical pharmacology and therapeutics 20061101

• Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo.

  The Journal of pharmacology and experimental therapeutics 20061001

• Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.

  Journal of clinical pharmacology 20061001

• Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease.

  Expert opinion on investigational drugs 20060901

• A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro.

  The Journal of allergy and clinical immunology 20060901

• The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.

  The Annals of pharmacotherapy 20060601

• Roflumilast for the treatment of chronic obstructive pulmonary disease.

  Current opinion in investigational drugs (London, England : 2000) 20060501

• Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline?

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20060501

• Efficacy and safety of roflumilast in the treatment of asthma.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20060501

• Phosphodiesterase inhibitors in airways disease.

  European journal of pharmacology 20060308

• Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.

  Expert opinion on pharmacotherapy 20060301

• Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.

  Pulmonary pharmacology & therapeutics 20060101

• Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma.

  Allergy 20060101

• Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.

  Respiratory research 20060101

• Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.

  Current medicinal chemistry 20060101

• Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.

  The Journal of pharmacology and experimental therapeutics 20051201

• The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20051201

• Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigs.

  The Journal of asthma : official journal of the Association for the Care of Asthma 20051201

• Roflumilast for chronic obstructive pulmonary disease.

  Lancet (London, England) 20051126

• Roflumilast for chronic obstructive pulmonary disease.

  Lancet (London, England) 20051126

• Roflumilast for chronic obstructive pulmonary disease.

  Lancet (London, England) 20051126

• Roflumilast for chronic obstructive pulmonary disease.

  Lancet (London, England) 20051126

• Roflumilast for chronic obstructive pulmonary disease.

  Lancet (London, England) 20051126

• AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).

  Current opinion in investigational drugs (London, England : 2000) 20051101

• Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.

  American journal of respiratory and critical care medicine 20051001

• Roflumilast for asthma and chronic obstructive pulmonary disease.

  Issues in emerging health technologies 20051001

• Roflumilast: a selective phosphodiesterase 4 inhibitor.

  Drugs of today (Barcelona, Spain : 1998) 20051001

• Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.

  The Journal of pharmacology and experimental therapeutics 20050801

• Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.

  The Journal of allergy and clinical immunology 20050801

• Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.

  Lancet (London, England) 20050801

• PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.

  Pharmacology & therapeutics 20050601

• Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease.

  Current opinion in pulmonary medicine 20050301

• Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.

  Lancet (London, England) 20050101

• The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro.

  Pulmonary pharmacology & therapeutics 20050101

• Structural basis for the activity of drugs that inhibit phosphodiesterases.

  Structure (London, England : 1993) 20041201

• Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones.

  Journal of enzyme inhibition and medicinal chemistry 20041201

• PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.

  Trends in pharmacological sciences 20040801

• PDE4 inhibitors in COPD--a more selective approach to treatment.

  Respiratory medicine 20040601

• [Recent development of new drugs for the treatment of allergic diseases].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20040501

• [Selective phosphodiesterase 4 inhibition. Controlling inflammation--also in patients with COPD].

  MMW Fortschritte der Medizin 20040429

• Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.

  The Journal of pharmacology and experimental therapeutics 20040201

• [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20040101

• Roflumilast: APTA 2217, B9302-107, BY 217, BYK 20869.

  Drugs in R&D 20040101

• Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma.

  The Journal of pharmacology and experimental therapeutics 20031001

• [Roflumilast: a new perspective in therapy of chronic obstructive lung disease].

  Pneumologia (Bucharest, Romania) 20030101

• Roflumilast Altana Pharma.

  Current opinion in investigational drugs (London, England : 2000) 20020801

• Inhibition of phosphodiesterase 4 in allergic rhinitis.

  Current allergy and asthma reports 20020501

• Phosphodiesterase 4 inhibitors for the treatment of COPD.

  Chest 20020501

• The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.

  Journal of clinical pharmacology 20020301

• Lack of DNA binding in the rat nasal mucosa and other tissues of the nasal toxicants roflumilast, a phosphodiesterase 4 inhibitor, and a metabolite, 4-amino-3,5-dichloropyridine, in contrast to the nasal carcinogen 2,6-dimethylaniline.

  Drug and chemical toxicology 20020201

• Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far.

  Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 20020201

• The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis.

  The Journal of allergy and clinical immunology 20011001

• Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.

  The Journal of pharmacology and experimental therapeutics 20010401

• In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.

  The Journal of pharmacology and experimental therapeutics 20010401